Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
PHASE3CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
August 30, 2017
Primary Completion Date
April 9, 2019
Study Completion Date
April 9, 2019
Conditions
Parathyroid CarcinomaPrimary Hyperparathyroidism
Interventions
DRUG
KHK7580
oral administration
Trial Locations (1)
Unknown
Osaka City University Hospital, Ōsaka
All Listed Sponsors
lead
Kyowa Kirin Co., Ltd.
INDUSTRY
NCT03280264 - Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism | Biotech Hunter | Biotech Hunter